Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Vertex Pharmaceutic (VRTX)

Vertex Pharmaceutic (VRTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 58,124,544
  • Shares Outstanding, K 254,252
  • Annual Sales, $ 6,206 M
  • Annual Income, $ 2,712 M
  • 60-Month Beta 0.64
  • Price/Sales 8.37
  • Price/Cash Flow 24.11
  • Price/Book 6.16
Trade VRTX with:

Options Overview Details

View History
  • Implied Volatility 41.42% ( +1.34%)
  • Historical Volatility 15.61%
  • IV Percentile 86%
  • IV Rank 66.32%
  • IV High 51.43% on 05/27/21
  • IV Low 21.70% on 09/07/21
  • Put/Call Vol Ratio 0.18
  • Today's Volume 418
  • Volume Avg (30-Day) 2,186
  • Put/Call OI Ratio 0.41
  • Today's Open Interest 19,111
  • Open Int (30-Day) 36,070

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate 2.90
  • Number of Estimates 8
  • High Estimate 3.10
  • Low Estimate 2.72
  • Prior Year 2.22
  • Growth Rate Est. (year over year) +30.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
214.66 +7.17%
on 01/03/22
234.58 -1.93%
on 01/14/22
+11.46 (+5.24%)
since 12/21/21
3-Month
179.96 +27.84%
on 11/23/21
234.58 -1.93%
on 01/14/22
+42.97 (+22.97%)
since 10/21/21
52-Week
176.36 +30.45%
on 10/06/21
242.99 -5.32%
on 01/25/21
-8.58 (-3.60%)
since 01/21/21

Most Recent Stories

More News
Will Higher Revenues Drive Corning's (GLW) Q4 Earnings?

Corning's (GLW) performance in the fourth quarter of 2021 is likely to have been primarily driven by growth in the Optical Communications business.

VRTX : 229.67 (+0.46%)
GLW : 35.66 (+1.51%)
MTH : 103.18 (+1.35%)
TSLA : 981.43 (-1.49%)
6 Must-Buy Large-Cap Stocks Ahead of Q4 Earnings Next Week

Six large-cap companies will report earnings next week. These are: TSLA, URI, FCX, VRTX, STLD and BRO.

STLD : 55.01 (-3.42%)
FCX : 42.40 (-1.83%)
VRTX : 229.67 (+0.46%)
BRO : 64.27 (+0.05%)
TSLA : 981.43 (-1.49%)
URI : 308.80 (+0.55%)
Will Vertex (VRTX) Beat Estimates Again in Its Next Earnings Report?

Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

VRTX : 229.67 (+0.46%)
4 Stocks With Impressive Interest Coverage Ratio to Invest In

A company that is capable of generating earnings well above its interest expense can withstand financial hardship. Companies such as ArcBest (ARCB), Advanced Micro Devices (AMD), AGCO Corporation (AGCO)...

AMD : 124.14 (+1.85%)
AGCO : 120.13 (+1.24%)
VRTX : 229.67 (+0.46%)
ARCB : 88.31 (-0.32%)
4 Reasons to Buy Vertex Pharmaceuticals (VRTX) Stock in 2022

New reimbursement agreements in ex-U.S. markets and label expansions to younger age groups are driving sales of Vertex's (VRTX) triple therapy cystic fibrosis drug, Trikafta/Kaftrio higher.

VRTX : 229.67 (+0.46%)
MRNA : 163.85 (-2.19%)
CRSP : 66.03 (+2.59%)
BNTX : 151.65 (-3.12%)
Will Lower Aggregate Revenues Hurt Verizon's (VZ) Q4 Earnings?

Verizon's (VZ) performance in the fourth quarter of 2021 is expected to have been affected by the sale of the Verizon Media unit.

VZ : 53.47 (+0.13%)
VRTX : 229.67 (+0.46%)
MTH : 103.18 (+1.35%)
TSLA : 981.43 (-1.49%)
Vertex Pharmaceuticals (VRTX) Stock Moves -0.1%: What You Should Know

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $230.84, marking a -0.1% move from the previous day.

VRTX : 229.67 (+0.46%)
Will 2022 Be a Better Year for Biotech Than 2021? 3 Big Picks

Regeneron (REGN), Vertex Pharmaceuticals (VRTX) and BioNTech (BNTX) are three large biotech stocks that are worth betting on in the current scenario.

REGN : 622.29 (+1.29%)
PFE : 52.93 (-2.07%)
VRTX : 229.67 (+0.46%)
BNTX : 151.65 (-3.12%)
The Zacks Analyst Blog Highlights: Bank of America Corp., Broadcom Inc., Royal Dutch Shell plc, Automatic Data Processing, Inc. and Vertex Pharmaceuticals Inc

Bank of America Corp., Broadcom Inc., Royal Dutch Shell plc, Automatic Data Processing, Inc. and Vertex Pharmaceuticals Inc are highlighted in this Analyst Blog article.

BAC : 45.97 (+0.48%)
ADP : 220.40 (+0.04%)
RDS.A : 48.91 (-1.17%)
VRTX : 229.67 (+0.46%)
AVGO : 553.16 (+0.99%)
4 Unstoppable Stocks That Can Run Circles Around Shiba Inu in 2022

These proven winners should handily outperform the world's hottest cryptocurrency.

^BTCUSD : 38,963.16 (-5.72%)
^BTCUSDT : 38,848.23 (-7.64%)
^ETHUSD : 2,846.052 (-7.50%)
^ETHUSDT : 2,844.115 (-7.73%)
^ETHBTC : 0.073061 (-2.11%)
BRK.A : 465,990.00 (-0.30%)
BRK.B : 310.64 (-0.12%)
VRTX : 229.67 (+0.46%)
CRWD : 172.03 (-1.07%)
GOOG : 2,692.35 (+0.83%)
GOOGL : 2,695.20 (+1.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs...

See More

Key Turning Points

3rd Resistance Point 238.82
2nd Resistance Point 236.62
1st Resistance Point 232.61
Last Price 229.67
1st Support Level 226.40
2nd Support Level 224.20
3rd Support Level 220.19

See More

52-Week High 242.99
Last Price 229.67
Fibonacci 61.8% 217.54
Fibonacci 50% 209.68
Fibonacci 38.2% 201.81
52-Week Low 176.36

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar